LLYELI LILLY & Co

NYSE lilly.com


$ 954.38 $ 2.20 (0.23 %)    

Thursday, 22-Aug-2024 15:59:59 EDT
QQQ $ 475.46 $ -7.65 (-1.59 %)
DIA $ 407.51 $ -1.51 (-0.37 %)
SPY $ 556.52 $ -4.40 (-0.78 %)
TLT $ 97.74 $ -0.98 (-0.99 %)
GLD $ 229.39 $ -2.78 (-1.2 %)
$ 954.17
$ 954.40
$ 954.14 x 200
-- x --
$ 948.00 - $ 972.25
$ 513.12 - $ 972.53
3,183,727
na
906.87B
$ 0.60
$ 123.51
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 04-27-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 04-29-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 10-27-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-17-2021 12-31-2020 10-K
16 10-28-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-19-2020 12-31-2019 10-K
20 10-25-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-19-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 07-25-2018 06-30-2018 10-Q
26 04-27-2018 03-31-2018 10-Q
27 02-20-2018 12-31-2017 10-K
28 10-27-2017 09-30-2017 10-Q
29 07-28-2017 06-30-2017 10-Q
30 05-01-2017 03-31-2017 10-Q
31 02-21-2017 12-31-2016 10-K
32 10-28-2016 09-30-2016 10-Q
33 07-28-2016 06-30-2016 10-Q
34 04-29-2016 03-31-2016 10-Q
35 02-19-2016 12-31-2015 10-K
36 10-30-2015 09-30-2015 10-Q
37 07-30-2015 06-30-2015 10-Q
38 04-30-2015 03-31-2015 10-Q
39 02-19-2015 12-31-2014 10-K
40 10-29-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oblique-therapeutics-enters-into-research-collaboration-agreement-with-eli-lilly-to-apply-abiprot-to-generate-antibodies-to-high-value-targets

https://www.prnewswire.com/news-releases/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and...

 wegovy-now-available-through-sesames-249-monthly-compounded-program-despite-supply-shortages

Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provi...

 novo-nordisk-vs-eli-lilly-beyond-the-weight-loss-drug-battle

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatmen...

 asia-mixed-european-markets-advance-gold-stays-near-all-time-high-while-dollar-gains---global-markets-today-while-us-slept

US stock markets close lower, breaking 8-day winning streak as investors pause before economic symposium. Energy stocks decline...

 wall-street-eases-bonds-rise-us-dollar-falls-to-8-month-low-whats-driving-markets-tuesday

It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices tr...

 eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-diabetes-sustained-weight-loss-over-3-years

Eli Lilly's SURMOUNT-1 three-year study reveals tirzepatide's effectiveness in reducing type 2 diabetes risk and achiev...

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $885 price target.

 telehealth-firm-hims--hers-health-rides-high-on-demand-for-copycat-weight-loss-drugs-amid-supply-shortages

Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss ...

 doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy

Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many pl...

 roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...

 guggenheim-maintains-buy-on-eli-lilly-raises-price-target-to-1030

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $884 to $1030.

 biden-administration-targets-6b-savings-through-medicare-drug-price-negotiations

Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.

 dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates

Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION